| scholarly article | Q13442814 |
| P2093 | author name string | Leppert M | |
| Slattery ML | |||
| Robertson M | |||
| Curtin K | |||
| Samowitz WS | |||
| Schaffer D | |||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1193-1197 | |
| P577 | publication date | 2000-11-01 | |
| P1433 | published in | Cancer Epidemiology, Biomarkers & Prevention | Q326334 |
| P1476 | title | Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study | |
| P478 | volume | 9 |
| Q53069742 | A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. |
| Q37283757 | A comparison of colon and rectal somatic DNA alterations |
| Q36089983 | A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens |
| Q35584153 | A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy |
| Q35402251 | A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases |
| Q37593331 | Adrenomedullin is a therapeutic target in colorectal cancer |
| Q34007796 | Alcohol consumption and rectal tumor mutations and epigenetic changes |
| Q53490424 | An Unusual Combination: KRAS and BRAF Co-mutated Metastatic Colorectal Cancer. |
| Q45834924 | An appraisal of lymph node ratio in colon and rectal cancer: not one size fits all. |
| Q42583248 | Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma |
| Q89843964 | Association Between Molecular Subtypes of Colorectal Tumors and Patient Survival, Based on Pooled Analysis of 7 International Studies |
| Q34759064 | Association between molecular subtypes of colorectal cancer and patient survival |
| Q36229011 | Association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in East Azerbaijan, Iran. |
| Q41862336 | Association of epidermal growth factor receptor and K-Ras mutations with smoking history in non-small cell lung cancer patients |
| Q34617200 | Associations between genetic variation in RUNX1, RUNX2, RUNX3, MAPK1 and eIF4E and riskof colon and rectal cancer: additional support for a TGF-β-signaling pathway |
| Q36540553 | Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics |
| Q33740175 | Associations of anthropometric factors with KRAS and BRAF mutation status of primary colorectal cancer in men and women: a cohort study |
| Q34517338 | BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients |
| Q37056074 | BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. |
| Q54325213 | BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. |
| Q35677900 | C/EBP-β-activated microRNA-223 promotes tumour growth through targeting RASA1 in human colorectal cancer |
| Q33727871 | Characterization of rare transforming KRAS mutations in sporadic colorectal cancer. |
| Q33959887 | Clinical relevance of KRAS in human cancers |
| Q34591262 | Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients |
| Q34010171 | Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways |
| Q27003134 | Colorectal Cancer Biomarkers: Where Are We Now? |
| Q35579056 | Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages |
| Q51033072 | Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping? |
| Q92838608 | Comparison of clinicopathological features and KRAS gene mutation of left-sided and right-sided colon cancers |
| Q34371471 | Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer. |
| Q34598203 | Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations |
| Q36487348 | Correlation between Gene Variants, Signaling Pathways, and Efficacy of Chemotherapy Drugs against Colon Cancers |
| Q33541307 | Dietary, lifestyle and clinicopathological factors associated with BRAF and K-ras mutations arising in distinct subsets of colorectal cancers in the EPIC Norfolk study |
| Q35652713 | Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations |
| Q35773077 | Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. |
| Q57056971 | Dual-specificity phosphatase 6 deletion protects the colonic epithelium against inflammation and promotes both proliferation and tumorigenesis |
| Q36790406 | EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma |
| Q34627605 | EGFR Signaling in Colorectal Carcinoma |
| Q92219419 | Exploring the Pharmacological Mechanism of the Herb Pair "HuangLian-GanJiang" against Colorectal Cancer Based on Network Pharmacology |
| Q28087333 | Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers |
| Q35584550 | External quality assessment for KRAS testing is needed: setup of a European program and report of the first joined regional quality assessment rounds |
| Q35024163 | Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma. |
| Q36610632 | Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumour clinicopathological features |
| Q37523207 | Genetic prognostic and predictive markers in colorectal cancer |
| Q35627924 | Genetic variability in EGFR, Src and HER2 and risk of colorectal adenoma and cancer. |
| Q53277819 | Genetic variability in IL23R and risk of colorectal adenoma and colorectal cancer. |
| Q35588474 | Genetic variation in C-reactive protein in relation to colon and rectal cancer risk and survival |
| Q34572197 | Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer |
| Q34094993 | Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. |
| Q30503444 | Genetic variation in bone morphogenetic protein and colon and rectal cancer |
| Q30498922 | Genetic variation in the TGF-β signaling pathway and colon and rectal cancer risk |
| Q36334742 | Genetic variation in the transforming growth factor-β signaling pathway and survival after diagnosis with colon and rectal cancer |
| Q35229101 | Global impact of KRAS mutation patterns in FOLFOX treated metastatic colorectal cancer |
| Q36469155 | Glutathione peroxidase tagSNPs: associations with rectal cancer but not with colon cancer |
| Q36113663 | High sensitivity isoelectric focusing to establish a signaling biomarker for the diagnosis of human colorectal cancer |
| Q36069872 | Identification of a common variant with potential pleiotropic effect on risk of inflammatory bowel disease and colorectal cancer |
| Q36775133 | Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy |
| Q37352557 | Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases |
| Q39094258 | Implication of K-ras and p53 in colorectal cancer carcinogenesis in Tunisian population cohort |
| Q37563971 | Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. |
| Q24629358 | Increased risk of colon cancer associated with a genetic polymorphism of SMAD7 |
| Q38761790 | Infrequently expressed miRNAs in colorectal cancer tissue and tumor molecular phenotype |
| Q35479013 | Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival |
| Q36315711 | Interleukin genes and associations with colon and rectal cancer risk and overall survival |
| Q33703112 | K-RAS mutation profile in Puerto Rican patients with colorectal cancer: trends from April 2009 to January 2011. |
| Q42922888 | K-Ras and MSI: potential markers of both patient prognosis and treatment efficacy |
| Q48097655 | KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study |
| Q39186065 | KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer. |
| Q35045790 | KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients |
| Q41136513 | KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer |
| Q27852414 | KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials |
| Q33693309 | KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). |
| Q37709323 | KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer |
| Q35233954 | KRAS mutation and microsatellite instability: two genetic markers of early tumor development that influence the prognosis of colorectal cancer |
| Q39642103 | KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis |
| Q27851532 | KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803 |
| Q37273361 | KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. |
| Q89845681 | KRAS mutations by digital PCR in circulating tumor cells isolated from the mesenteric vein are associated with residual disease and overall survival in resected colorectal cancer patients |
| Q36097103 | KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy |
| Q51701640 | KRAS testing and its importance in colorectal cancer. |
| Q36889656 | KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers |
| Q38765961 | KSR1 and EPHB4 Regulate Myc and PGC1β To Promote Survival of Human Colon Tumors |
| Q34585656 | Krüppel-like factor 5 mediates cellular transformation during oncogenic KRAS-induced intestinal tumorigenesis |
| Q42777241 | Left and right sided large bowel cancer |
| Q30528832 | MAP kinase genes and colon and rectal cancer |
| Q33746903 | Microarray applications in cancer research |
| Q33954707 | Microsatellite instability and survival in rectal cancer |
| Q35737549 | Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution |
| Q30807030 | Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature |
| Q34665492 | Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes |
| Q24620628 | Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field |
| Q37878380 | Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports |
| Q52633432 | Mutation analysis of adenomas and carcinomas of the colon: Early and late drivers. |
| Q33412122 | Mutation detection by real-time PCR: a simple, robust and highly selective method |
| Q90241844 | Mutation profiling of cancer drivers in Brazilian colorectal cancer |
| Q21261222 | Mutations in APC, CTNNB1 and K-ras genes and expression of hMLH1 in sporadic colorectal carcinomas from the Netherlands Cohort Study |
| Q54591533 | Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. |
| Q49679318 | Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer |
| Q33534522 | Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer |
| Q50679391 | Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer. |
| Q30368810 | Novel KRAS gene mutations in sporadic colorectal cancer |
| Q37241845 | Oncogene Mutations in Colorectal Polyps Identified in the Norwegian Colorectal Cancer Prevention (NORCCAP) Screening Study |
| Q37091527 | Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. |
| Q34749595 | Oncogenic K-ras promotes early carcinogenesis in the mouse proximal colon |
| Q36050773 | PTEN mRNA expression is less pronounced in left- than right-sided colon cancer: a retrospective observational study |
| Q50080288 | Patterns and the Occurrence of KRAS Mutations in Metastatic Colorectal Cancers-a Study from Indian Regional Cancer Centre |
| Q33401352 | Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer |
| Q37051209 | Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens |
| Q37172368 | Phospholipase A2G1B polymorphisms and risk of colorectal neoplasia. |
| Q37107712 | Prognostic role of KRAS mutations in Sardinian patients with colorectal carcinoma |
| Q35012132 | Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer |
| Q38600228 | Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis. |
| Q42139232 | RAS mutations vary between lesions in synchronous primary colorectal cancer: testing only one lesion is not sufficient to guide anti-EGFR treatment decisions. |
| Q98771157 | Relevance of Pharmacogenomics and Multidisciplinary Management in a Young-Elderly Patient With KRAS Mutant Colorectal Cancer Treated With First-Line Aflibercept-Containing Chemotherapy |
| Q36121090 | Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab |
| Q33599123 | Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis |
| Q38104294 | Role of targeted agents in metastatic colorectal cancer. |
| Q40773360 | Sensitive and specific detection of K-ras mutations in colon tumors by short oligonucleotide mass analysis |
| Q37355802 | Sex differences in the prognostic significance of KRAS codons 12 and 13, and BRAF mutations in colorectal cancer: a cohort study |
| Q39139086 | Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer |
| Q36761405 | Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers |
| Q37023898 | Statistical strategies to improve the efficiency of molecular studies of colorectal cancer prognosis |
| Q36185880 | TERT's role in colorectal carcinogenesis |
| Q34616409 | The role of oncogenes in gastrointestinal cancer |
| Q42111689 | Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer |
| Q35576313 | Variation in the CYP19A1 gene and risk of colon and rectal cancer |
| Q34622865 | Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) |
Search more.